16
Participants
Start Date
November 30, 2010
Primary Completion Date
December 31, 2016
Study Completion Date
January 31, 2017
Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
The researchers will multiply/expand the Tregs in the laboratory using anti-CD3/anti-CD28 coated beads plus IL-2. Then, the Tregs will be infused back into the patient in a single infusion. The first cohort will receive 0.05 x10\^8 cells. The second cohort will receive 0.4 x10\^8 cells. The third cohort will receive 3.2 x10\^8 cells. The fourth cohort will receive 26 x10\^8 cells.
University of California, San Francisco Medical Center, San Francisco
Yale University, New Haven
Collaborators (1)
Juvenile Diabetes Research Foundation
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
University of California, San Francisco
OTHER